Bio-psycho-social Pathways Underlying the Effects of Qigong Among Comorbid Depressed Elderly With Chronic Conditions

July 29, 2018 updated by: TSANG Hector Wing-Hong, The Hong Kong Polytechnic University
Depression and chronic medical conditions are common in older adults. Qigong is increasingly documented to have anti-depressive effects for older adults. Nevertheless, the scientific concepts behind qigong remain a mystery. To fill the knowledge gap, the neurobiological mechanism of the effects of qigong was explored. In addition, the benefits of qigong on subjective well-being, functional independence, sleep quality, mobility, and muscle strength were also tested. After random assignment, intervention group (n = 14) went through individual qigong exercise twice a week and for 12 weeks,whereas control group (n = 16) was involved in cognitive training activities with mobilization elements. The psychosocial, physical, and neurobiological outcomes of the two groups were compared.

Study Overview

Study Type

Interventional

Enrollment (Actual)

35

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hong Kong, Hong Kong
        • The Hong Kong Polytechinic University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • aged 60 or above
  • have been suffering from chronic medical conditions for more than one year
  • have depressive symptoms as indicated by Geriatric Depression Scale (GDS ≥ 6)

Exclusion Criteria:

  • have practiced or received training of any form of mind-body exercises (including tai chi, yoga, and qigong) during the 6 months prior to intervention.
  • have changed medication or the dosage prior to or during intervention
  • have obvious cognitive and language impairment or score less than 20 in Mini-Mental State Examination (MMSE)
  • undergo electroconvulsive therapy, psychotherapy, or psychoeducation
  • cannot demonstrate satisfactory sitting balance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Cognitive Training
Cognitive Training of Memory and Executive Function with Activities requiring Mobilization
Experimental: Qigong Training
Eight-Section Brocades; participants were trained individually.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Health Questionnaire (PHQ)
Time Frame: the change from baseline to the completion of intervention (12 weeks later)
Patient Health Questionnaire (PHQ) is used to assess the experience of depressive symptoms. The frequency of each symptom was indicated based on a 4-point scale (0 = never; 3 = almost every day). A total score ranged from 0 to 27 can be derived, with higher score indicating severer depressive symptoms.
the change from baseline to the completion of intervention (12 weeks later)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Salivary Cortisol Level
Time Frame: baseline and 12 weeks after baseline
measured with saliva sample obtained 5 times (07:00, 10:30, 13:00, 14:30, and 18:00) at two consecutive days at baseline and 12 weeks after baseline
baseline and 12 weeks after baseline
Brain Deprived Neurotrophic Factor (BDNF) Level
Time Frame: baseline and 12 weeks after baseline
measured with peripheral blood samples (10 ml) collected in the morning
baseline and 12 weeks after baseline
Serotonin 5-HT Level
Time Frame: baseline and 12 weeks after baseline
measured with serum extracted from blood samples. Around 2-3 ml of serum is harvested per 5 ml of blood.
baseline and 12 weeks after baseline
Depression Anxiety Stress Scale (DASS-21)
Time Frame: baseline, 12 weeks after baseline, and 16 weeks after baseline
Depression Anxiety Stress Scale (DASS-21) is a 21-item scale to measure symptoms of depression, anxiety, and stress with 7 items for each. Each item is measured with 4-point from 0 (never) to 3 (almost always). The scores of depression, anxiety, and stress are the sum of all subscale items, and it can range from 0 to 21. Higher score shows more severity of depression, anxiety, and stress.
baseline, 12 weeks after baseline, and 16 weeks after baseline
Personal Well-Being Index (PWI)
Time Frame: baseline, 12 weeks after baseline, and 16 weeks after baseline
It is measured by the 8-item scale of Personal Well-Being Index (PWI). Each item was rated according to an 11-point scale ranging from '0' (extremely dissatisfied) to '10' (extremely satisfied). An overall score of PWI score was the sum of all items. The overall score ranges from 0 to 110, with higher score indicating higher subjective well-being.
baseline, 12 weeks after baseline, and 16 weeks after baseline
Functional Independence Measure (FIM)
Time Frame: baseline, 12 weeks after baseline, and 16 weeks after baseline

It is measured by the 18-item scale of Functional Independence Measure (FIM). Based on a 7-point scale for rating (1

= totally unable; 7 = totally independent), a total score of FIM ranges from 18 to 126 was generated. Higher total score indicates less disability.

baseline, 12 weeks after baseline, and 16 weeks after baseline
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: baseline, 12 weeks after baseline, and 16 weeks after baseline
It is measured by the Pittsburgh Sleep Quality Index (PSQI). It has 19 items measuring 7 components of sleep quality, and a total score is calculated as the sum of all the component scores. The total score ranges from 0 to 21, with lower score showing better sleep quality.
baseline, 12 weeks after baseline, and 16 weeks after baseline
Timed up and Go Test (TUG)
Time Frame: baseline, 12 weeks after baseline, and 16 weeks after baseline

Timed up and Go Test (TUG) is used to measure mobility. During the test, participants were sitting on a chair, and then they were required to stand up, walk to a mark which is 3 meters away from the chair, go back to the chair from the mark, and sit down again. The time each participant spent to complete the above series of actions was recorded.

Participants performed the test for three times, and their final scores were the average of the three. And lower score indicates better mobility.

baseline, 12 weeks after baseline, and 16 weeks after baseline
Handgrip Strength
Time Frame: baseline, 12 weeks after baseline, and 16 weeks after baseline
It is measured with a Jamar handheld dynamometer. Participants performed three trials of left hand and right hand grip strength, and the final outcome of each hand was calculated as the mean performance of the three trials. Higher score indicates stronger handgrip strength.
baseline, 12 weeks after baseline, and 16 weeks after baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2017

Primary Completion (Actual)

January 31, 2018

Study Completion (Actual)

February 28, 2018

Study Registration Dates

First Submitted

June 26, 2018

First Submitted That Met QC Criteria

July 8, 2018

First Posted (Actual)

July 19, 2018

Study Record Updates

Last Update Posted (Actual)

July 31, 2018

Last Update Submitted That Met QC Criteria

July 29, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Other Study ID Numbers

  • 81173316-2

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Disease

Clinical Trials on Qigong Training

Subscribe